scholarly journals Mutation of Tyrosine 470 of Human Dopamine Transporter is Critical for HIV-1 Tat-Induced Inhibition of Dopamine Transport and Transporter Conformational Transitions

2013 ◽  
Vol 8 (4) ◽  
pp. 975-987 ◽  
Author(s):  
Narasimha M. Midde ◽  
Xiaoqin Huang ◽  
Adrian M. Gomez ◽  
Rosemarie M. Booze ◽  
Chang-Guo Zhan ◽  
...  
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Wei-Lun Sun ◽  
Pamela M. Quizon ◽  
Yaxia Yuan ◽  
Matthew J. Strauss ◽  
Richard McCain ◽  
...  

Author(s):  
Pamela M. Quizon ◽  
Yaxia Yuan ◽  
Yike Zhu ◽  
Yi Zhou ◽  
Matthew J. Strauss ◽  
...  

AbstractHIV-1 transactivator of transcription (Tat) has a great impact on the development of HIV-1 associated neurocognitive disorders through disrupting dopamine transmission. This study determined the mutational effects of human dopamine transporter (hDAT) on basal and Tat-induced inhibition of dopamine transport. Compared to wild-type hDAT, the maximal velocity (Vmax) of [3H]dopamine uptake was decreased in D381L and Y88F/D206L/H547A, increased in D206L/H547A, and unaltered in D206L. Recombinant TatR1 − 86 inhibited dopamine uptake in wild-type hDAT, which was attenuated in either DAT mutants (D206L, D206L/H547A, and Y88F/D206L/H547A) or mutated TatR1 − 86 (K19A and C22G), demonstrating perturbed Tat-DAT interaction. Mutational effects of hDAT on the transporter conformation were evidenced by attenuation of zinc-induced increased [3H]WIN35,428 binding in D206L/H547A and Y88F/D206A/H547A and enhanced basal MPP+ efflux in D206L/H547A. H547A-induced outward-open transport conformational state was further validated by enhanced accessibility to MTSET ([2-(trimethylammonium)ethyl]-methanethiosulfonate) of an inserted cysteine (I159C) on a hDAT background.. Furthermore, H547A displayed an increase in palmitoylation inhibitor-induced inhibition of dopamine uptake relative to wide-type hDAT, indicating a change in basal palmitoylation in H547A. These results demonstrate that Y88F, D206L, and H547A attenuate Tat inhibition while preserving DA uptake, providing insights into identifying targets for improving DAT-mediated dopaminergic dysregulation. Graphical Abstract HIV-1 Tat inhibits dopamine uptake through human dopamine transporter (hDAT) on the presynaptic terminal through a direct allosteric interaction. Key hDAT residues D-H547, D-Y88, and D-D206 are predicted to be involved in the HIV-1 Tat-DAT binding. Mutating these residues attenuates this inhibitory effect by disrupting the Tat-hDAT interaction


2015 ◽  
Vol 10 (1) ◽  
pp. 122-135 ◽  
Author(s):  
Narasimha M. Midde ◽  
Yaxia Yuan ◽  
Pamela M. Quizon ◽  
Wei-Lun Sun ◽  
Xiaoqin Huang ◽  
...  

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Pamela M. Quizon ◽  
Wei-Lun Sun ◽  
Yaxia Yuan ◽  
Narasimha M. Midde ◽  
Chang-Guo Zhan ◽  
...  

Structure ◽  
2015 ◽  
Vol 23 (11) ◽  
pp. 2171-2181 ◽  
Author(s):  
Mary Hongying Cheng ◽  
Ivet Bahar

2017 ◽  
Vol 292 (46) ◽  
pp. 19066-19075 ◽  
Author(s):  
Sathya Challasivakanaka ◽  
Juan Zhen ◽  
Margaret E. Smith ◽  
Maarten E. A. Reith ◽  
James D. Foster ◽  
...  

2008 ◽  
Vol 283 (25) ◽  
pp. 17691-17701 ◽  
Author(s):  
Julie Kniazeff ◽  
Lei Shi ◽  
Claus J. Loland ◽  
Jonathan A. Javitch ◽  
Harel Weinstein ◽  
...  

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Alon Herschhorn ◽  
Christopher Gu ◽  
Francesca Moraca ◽  
Xiaochu Ma ◽  
Mark Farrell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document